Three D-type cyclins, cyclin D1, D2 and D3, belong to the G1 cyclin, which regulates the G1/S transition of the cell cycle, and feature highly homologous amino acid sequences. The cyclin D1 gene was found to be transcriptionally activated in B-lymphoid malignancies with t(11;14), but available information is limited regarding expression of cyclin D2 and D3 in hematopoietic malignancies. We examined the expressions of three D-type cyclins to investigate how these homologous genes are differentially used. Northern blot hybridization with densitometric analyses was performed to examine 64 cell lines and 159 patients with various hematopoietic malignancies. Among lymphoid malignancies, cyclin D1 overexpression was exclusively detected in B cell malignancies accompanied by a genetic event consisting of 11q13 chromosomal translocation, consisting of 13 of 19 (68%) patients with mantle cell lymphoma, two of 11 (18%) with B-chronic lymphocytic leukemia, and one of six (17%) with multiple myeloma. The cyclin D2 expression was significantly higher in T cell malignancies than in B cell malignancies (P = 0.003 for cell lines and P Ͻ 0.0001 for patient samples, respectively). In the T cell malignancies, cyclin D2 overexpression was predominantly recognized in those with mature phenotype. Furthermore, cyclin D2 expression was upregulated by phytohemagglutinin (PHA) stimulation of normal T-lymphocytes, suggesting that this simply represents the proliferation status of mature T cells. Although cyclin D3 was ubiquitously expressed, its expression was reduced in lymphoid malignancies with cyclin D1 or D2 overexpression. In myeloid leukemias, although three D-type type cyclins were differentially expressed, no preference for particular D-type cyclins was found. This selective usage of D-type cyclins in lymphoid malignancies suggests an existence of a regulatory mechanism among three D-type cyclins.
Introduction
Cyclins were first identified as proteins whose levels fluctuate dramatically during the cell cycle, 1 but later they came to be recognized as regulatory subunits for serine/threonine kinases of the cdc2 or cyclin-dependent kinase family. 2 Cyclin D1, first identified as a PRAD1 gene product in parathyroid adenomas, [3] [4] [5] was cloned by the rescue of a budding yeast lacking G1 cyclins. 6, 7 Separately, three murine cyclin-like genes, CYL1, CYL2 and CYL3, were isolated as colony-stimulating factor 1 responsive genes, and CYL1 was proved to be the murine cyclin D1 gene. 8 Human cyclin D2 and D3 were identified as homologues of the murine CYL2 and CYL3 genes. 9, 10 In B cell malignancies with 11q13 translocation, BCL-1 locus on chromosome 11, just upstream of cyclin D1 gene, fuses to the immunoglobulin heavy chain gene on chromo-some 14, [11] [12] [13] in much the same way as the c-myc gene is affected by t (8;14) translocations in Burkitt's lymphoma 14 and the BCL-2 gene by t(14;18) translocations in follicular lymphomas. 15 The breakpoints occur at variable distances from the cyclin D1 gene, typically up to 120 kb, but the net effect appears to be the transcriptional activation of cyclin D1. 12, 13, [16] [17] [18] Several groups including ours have reported cyclin D1 overexpression in B cell malignancies, ie mantle cell lymphoma (MCL), [18] [19] [20] [21] [22] [23] splenic marginal zone lymphoma, 24 hairy cell leukemia, 20, 25 chronic lymphocytic leukemia (CLL), 20, 26 and multiple myeloma/plasma cell leukemia. 18, 27, 28 In solid tumors, amplification and overexpression of cyclin D1 gene have been demonstrated in a variety of human cancers including breast carcinomas, 29, 30 head and neck squamous cell carcinomas, 29, 31 and hepatocellular carcinomas. 32 Furthermore, mice containing an MMTV-cyclin D1 transgene were reported to develop breast tumors, thereby confirming in vivo that cyclin D1 is indeed an oncogene. 33 An increased cyclin D2 expression has been reported in B-CLL cases 34 and human T-lymphotropic virus type I (HTLV-I) infected T cell lines. 35 Although no translocational activation of the cyclin D2 gene has been found in human cancers, cyclin D2 amplification was noted in colorectal cancer, 36 B cell lymphoma 37 and B-CLL. 38 Cyclin D3 gene has not yet been identified as a proto-oncogene.
The three D-type cyclins are highly homologous in amino acid sequences in the cyclin box (homology 73-83%), comparing with other types of cyclin A, B, C, and E (21-36%). 10 In addition, these three D-type cyclins possess similar function to regulate the cell cycle of G1/S phase transition. 39, 40 In spite of the similarities in sequence and function, their chromosomal localizations are different: cyclin D1 is located at 11q13, cyclin D2 at 12p13, and cyclin D3 at 6p21, indicating that they may possess different biological roles. The expression of these D-type cyclins has not yet been examined systematically in hematopoietic malignancies, and it thus remains unclear how these three similar genes are used in the hematopoietic system. We therefore investigated their correlative expression in various hematopoietic malignancies to clarify the difference and the biological significance in employment of these three D-type cyclins.
Materials and methods

Cell lines
The cell lines used in this study are listed in Table 1 . All these cell lines were grown in suspension at between 0.2 and 1.0 × 10 6 cells/ml in RPMI 1640 medium containing 10% fetal calf serum. Cultures for FLAM-76 required an additional 4 ng/ml of interleukin-6, for IPAT-1, KPNT-1 and WHN-2, 70 U/ml of interleukin-2, and those for SKNO-1 and OIH-1, 10 ng/ml of granulocyte-macrophage colony-stimulating factor.
Patients
A total of 159 patients with various hematopoietic malignancies diagnosed at Aichi Cancer Center Hospital, Nagoya, Japan was examined. These patients consisted of nine cases of precursor B-lymphoblastic leukemia, 20 of diffuse large B cell lymphoma (DLBL), 21 of follicular center cell lymphoma (FCL), 19 of MCL, 11 of B-CLL, six of myeloma, seven of precursor T-lymphoblastic leukemia/lymphoma (T-ALL/LBL), four of peripheral T cell lymphoma (PTCL), 21 of adult T cell leukemia (ATL) and 31 of acute myeloid leukemia (AML). The clinical records of all these cases were reviewed. The diagnosis of the lymphoid malignancies was based on REAL classification, 41 and of AMLs on French-American-British classification. 42, 43 For patients with leukemia, bone marrow or peripheral blood samples containing more than 80% of leukemic cells were selected for this study. For patients with lymphoma, biopsied specimens containing more than 50% of lymphoma cells determined by flow cytometric analyses at diagnosis were selected, and those with less tumor cells were excluded from this study.
Peripheral blood lymphocytes
Peripheral blood lymphocytes (PBL) were obtained from normal volunteers under informed consent, and were separated by Ficoll-Hypaque gradient centrifugation. Anti-CD4, anti-CD8 and anti-CD19 monoclonal antibodies combined with immunomagnetic beads (MBL, Nagoya, Japan) were used for fractionation of T cells and B cells, according to the manufacturer's protocol. The PBLs obtained from healthy individuals were cultured in RPMI 1640 with 10% fetal calf serum in the presence of 30 g/ml PHA-P (Difco Laboratories, Detroit, MI, USA) in a 5% CO 2 incubator at 37°C for 1 to 48 h.
Northern blot analysis
Total RNA was extracted with the guanidinium isothiocyanate and cesium chloride method. Five micrograms of total RNA was applied to each lane and Northern blot analyses were performed using Hybond-N plus filter (Amersham-Japan, Tokyo) by capillary blotting method according to the manufacturer's instructions. Probes were radiolabeled using a random primer DNA labeling kit (Nippon gene, Tokyo) with ␣-32 P-dCTP. Sheared human placenta DNA was included in the hybridization solution at a concentration of 100 g/ml to eliminate cross-hybridization with ribosomal RNA. Washing conditions were done to a final stringency of 0.1 × SSC, 0.1% SDS, 65°C. Total RNA from cell line ZR75-1 for cyclin D1, Hut102 for cyclin D2 and Raji or CMK cell lines for cyclin D3 were applied to each gel as a standard for Northern analysis ( Figure 1 ). The probes used for cyclin D1 mRNA expression was a 0.9 kb PstI/HindIII fragment of the cDNA clone P1-4, which contained a part of the open reading frame (ORF), a kind gift from Dr Andrew Arnold. 4 Human cyclin D2 cDNA probe was a 0.85 kb total ORF fragment, a generous gift from Dr Gordon Peters. 44 The cyclin D3 probe was a 2.0 kb cDNA clone A7, generously provided by Dr Andrew Arnold. 45 The loading and integrity of the RNA on each gel were checked by 28S ribosomal RNA level visualized by ethidium bromide staining. A part of the examination was performed by reprobing the filters for the detection of different cyclins after confirming the reproducibility of the reprobing. For comparison, films exposed for 24-h were used for densitometric analysis.
Densitometric analysis
Densitometric scanning of autoradiographic signals was performed by using an Image Analyzer V10 (Toyobo, Osaka, Japan). The cyclin D1 signal of ZR75-1 was arbitrarily defined as 100% and the expressions of each of the sample were calculated and then corrected according to the corresponding 28S ribosomal RNA levels on ethidium bromide staining. The standard intensity for cyclin D2 (Hut 102 cell line) was calculated as 170 relative percent, and that for cyclin D3 (Raji or CMK) as 100%. The expression of all other cell lines and patient samples was evaluated by comparing with these standards. The values from patient samples were re-corrected according to the tumor cell ratio determined by phenotypic analyses. Expression levels of less than 5 relative percent were defined as no expression. Because cyclin D1 is silent in normal lymphocytes, detectable expression of cyclin D1 was regarded as overexpression. Overexpression of cyclin D2 and D3 was defined as an expression higher than that of PBL for lymphoid malignancies, and that of bone marrow mononuclear cells for myeloid leukemias. Statistical analyses for comparison of the two groups were performed with 2 tests.
Results
D-type cyclin expression in cell lines
In 
D-type cyclin expression in patients' tumors
The results are summarized in Table 2 . Cyclin D1 expression was observed in 16 patients with B cell malignancies, but none with T cell malignancies. These cyclin D1 overexpressing malignancies included 13 of 19 MCLs, two of 11 B-CLLs, one of six myelomas. In the myeloid malignancies, the cyclin D1 overexpression was also infrequently seen in two of 31 AMLs.
Cyclin D2 was expressed in 24 patients with B cell, 24 with T cell, and 21 with myeloid neoplasms. It was identified as overexpression in four of nine precursor-B ALLs, one of 20 DLBLs, one of 21 FCLs, two of 11 B-CLLs, one of six myelomas, three of seven T-ALL/LBLs, three of four PTCLs and 15 of 21 ATLs, with a significantly higher incidence in T cell than in B cell neoplasms (P Ͻ 0.0001).
Cyclin D3 was expressed in the majority of the cases examined. However, its expression was reduced in lymphoid malignancies with cyclin D1 or D2 overexpression, while it was not always decreased in AML cases, supporting the observation in the cell lines. Namely, overexpression of cyclin D3 was observed in all of nine pre-B ALLs, 12 of 20 DLBLs, 13 of 21 FCLs, one of 19 MCLs, six of 11 B-CLLs, three of six myelomas, three of seven T-ALL/LBLs, one of four PTCLs and two of 21 ATLs, with significantly higher incidence in B cell than in T cell neoplasms (P = 0.0013).
Relationship between cyclin D1 overexpressing B-lineage cases and 11q13 status
In 13 cases of MCL with cyclin D1 overexpression, cytogenetic data was available in five cases. Although one of the five cases showed normal karyotype (46,XX), the remaining four cases demonstrated cytogenetic abnormalities including 11q13 translocation; three with t(11;14)(q13;q32) and one with t(11;22)(q13;q11). Another five cases were proved to have 11q13 translocation by Southern blotting, and three cases (including the one case with normal karyotype) showed germline configuration. In six cases of MCL without cyclin D1 mRNA expression, one case showed abnormal karyotype with 45,XY,−20,del(11)(q23). Using Southern blotting analyses, no genetic rearrangement was found in five cases examined including the one karyotyped case.
In two cases of B-CLL with cyclin D1 overexpression, one showed complexed karyotypes including an 11q13 abnormality, and the other, a normal karyotype. One case of myeloma with cyclin D1 overexpression showed a karyotype with 46,XY,t(11;14)(q13;q32).
D-type cyclin expression in normal lymphocytes
Cyclin D1 expression was not recognized in either the stimulated or unstimulated lymphocytes derived from healthy volunteers (Figure 3) . Although both cyclin D2 and D3 were Northern blot analysis of various hematopoietic cell lines with D-type cyclins. 5 g of total RNA was applied to each lane. ZR 75-1, Hut102 and CMK were used as positive controls of cyclins D1, D2 and D3, respectively. Only one D-type cyclin was expressed in SKNO-1 (cyclin D2), THP1 and U937 (cyclin D3), whereas all three were expressed in HL60 and ME-1R cell lines.
expressed in T cells and B cells, cyclin D2 expression was higher in T cells, while cyclin D3 in B cells. The expression level of cyclin D2 was increased more than 10 times in 2 to 6 h by PHA-P stimulation, while that of cyclin D3 was once decreased in 1 to 2 h and then increased in 6 to 12 h.
Discussion
In the present study, cyclin D1 expression was observed in the majority of MCLs, as well as in a subset of B-CLLs and myelomas, but not in the other B cell or T cell malignancies. All these cyclin D1 positive cases were restricted in the neoplasms having possibilities to possess 11q13 translocations. This exclusive detection of cyclin D1 overexpression in these diseases is considered to reflect a genetic alteration of cyclin D1 gene in lymphoid malignancies, which is in line with the literature. 46 Indeed, nine of the 13 cases of MCL with cyclin D1 overexpression showed cytogenetic and/or genetic abnormality of 11q13 region. Because cytogenetic analysis is not always informative due to a low proliferative rate in lymphoma cells and Southern blotting analysis is not always capable of detecting all of the 11q13 translocation due to the wide range of the breakpoint region, the negative result from cytogenetic or Southern blotting analysis does not necessarily exclude the presence of 11q13 translocation. In MCL, six cases (32%) did not express cyclin D1, and the results were in line with those from immunohistochemical, karyotypic and genetic analyses. These cyclin D1-negative MCL cases fulfilled the morphological criteria of MCL, and might constitute a distinct entity from cyclin D1-positive typical MCL, as has been proposed by our group. 23 Cyclin D1 expression was also observed in seven myeloid leukemia cell lines and two patient samples derived from AML, although the expression levels were lower than those in B cell malignancies bearing 11q13 translocations. All of these myeloid samples did not have 11q13 translocations by karyotypic analyses, thus an as yet unknown mechanism other than genetic translocation might be responsible for this unusual expression of cyclin D1 in myeloid leukemia. The incidence of cyclin D1 expression in cell lines derived from AML and myeloma was conspicuously higher than in patient samples. It seems likely that cyclin D1 expression enhances growth advantage and is responsible for the subsequent establishment of cell lines, as has been reported in p16/MTS1/INK4A tumor suppressor gene alteration in various tumors. 47 Cyclin D2 overexpression has been reported in ATL cell lines, and was attributed to HTLV-I infection and Tax1 gene involvement. 35 In our study, however, this overexpression was observed in the majority of mature T cell malignancies including those without HTLV-I association. These include the ATL-5T and WHN-2 cell lines, established from HTLV-I negative ATL. 48, 49 Moreover, in the present study, cyclin D2 expression level was demonstrated to be increased by PHA stimulation in normal T cells from healthy volunteers not infected with HTLV-I. These data suggested that the cyclin D2 overexpression in T cell lineage represented the proliferation of mature T cells, and was not necessarily caused by HTLV-I infection nor Tax1 gene involvement. Indeed, in ATL patient samples, cyclin D2 expression levels were lower than those in ATL cell lines, which might reflect their respective activation status or cytokine levels in the culture medium.
Cyclin D2 expression has also been reported in B-CLL and lymphoplasmacytic lymphoma cases. 34 Werner et al 38 described that 29 of 34 B-CLL cases expressed cyclin D2, although cyclin D3 expression was not detected in their 10 cases examined. In our present study, although the number is relatively small, expression of cyclin D2 and D3 was observed in five and 10 out of 11 cases, respectively, which was somewhat different from the data of Werner et al. Because B-CLL is rather rare in Japan compared with Western countries, 50 the incidence of cyclin D2 expression in B-CLL might reflect epidemiological differences as mentioned in the low incidence and frequencies of BCL-2 rearrangement in Japanese follicular lymphoma. 51, 52 These discrepancies do not deny the possi-
Figure 2
The expression level of D-type cyclins in cell lines. Northern blot films were scanned with densitometer and the expressions of each sample were calculated and were corrected by the 28S ribosomal RNA levels on ethidium bromide staining. The cyclin D1 signal of ZR75-1 cell line was arbitrarily defined as 100%, and the cyclin D2 expression of Hut102 (170%) and cyclin D3 expression of Raji or CMK (100%) were used as standard for each cyclin. The levels less than 5 relative percent were defined as no expression. bility that cyclin D2 acts as a candidate oncogene in B-CLL, but further investigations are needed to determine the significance of cyclin D2 expression in B-CLL.
Reports on murine CYL-1, CYL-2 and CYL-3 suggest that the expression of cyclin D2 is ubiquitous in growth factordependent hematopoietic cells, whereas that of cyclin D1 and cyclin D3 is restricted to macrophages and T cells, respectively. 8 This is clearly not the case with the human hematopoietic malignancies analyzed in the present study. Our data confirmed that cyclin D1 is silent in lymphoid malignancies without 11q13 translocations, and demonstrated that cyclin D3 rather than cyclin D2 was ubiquitously expressed. Cyclin D3 expression was generally high in B cell malignancies and even in normal B cells, but was reduced in MCL and multiple myeloma in which cyclin D1 or D2 was overexpressed. This agrees with the recent report of Ott et al, 53 describing low or missing expression of cyclin D3 in MCL. In the normal and neoplastic cells of T cell lineage, cyclin D3 and D2 were preferentially expressed in their immature and mature stage, respectively. It is similarly suggested in the mature T cells that cyclin D2 is expressed through the cell cycle of G1/S transition, and cyclin D3 is consecutively downregulated. In PHAstimulated normal PBLs, cyclin D3 expression decreased in the first 1 to 2 h and subsequently upregulated in 12 to 24 h. Because PBLs are a heterogeneous population including T cells and B cells, it is possible that cyclin D2 upregulation in PHA-stimulated PBLs reflects a direct activation of T cells, and that later upregulation of cyclin D3 arises from B cells stimulated by certain factors derived from PHA-activated T cells. 54 Three D-type cyclins are differentially and selectively expressed in lymphoid malignancies, suggesting their different role in the cell cycle control and the oncogenic activities.
Regarding myeloid leukemias, no tendencies in the expression of three D-type cyclins were recognized in contrast to lymphoid malignancies. All three D-type cyclins are expressed with a variable intensity in myeloid cell lines, HL-60, NKM-1, ME-1R, IMS-M1 and Meg-01. On the other hand, none of the three cyclin Ds was expressed in three AML (two M0 and one M4) case, which was not observed in any of the lymphoid malignancies. It is suggested that certain other molecules might substitute the function of D-type cyclins in these cases. Also, further investigation is needed to identify how these three D-type cyclins are differentially employed in myeloid malignancies.
In conclusion, selective usage of three D-type cyclins in lymphoid malignancies suggests the existence of an underlying regulatory mechanism and a functional difference of these three D-type cyclins. The fact that no preference for particular D-type cyclins was found in myeloid leukemia suggests that such a regulatory mechanism may operate predominantly in lymphoid lineage.
